Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a biopharmaceutical firm, announced CEO Anthony Sun's participation in virtual investor conferences. The events include the Guggenheim Oncology Conference on February 10, 2022, at 10:30 a.m. EST, and the SVB Leerink 2022 Global Healthcare Conference on February 17, 2022, at 1:00 p.m. EST. Webcasts will be available on Zentalis's website post-event. The company focuses on developing innovative cancer therapies, including ZN-c3, ZN-c5, ZN-d5, and ZN-e4, targeting various cancer types.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) is hosting a virtual R&D Day on December 16, 2021, from 11:00 a.m. to 12:00 p.m. EST. The event will feature management and three Key Opinion Leaders discussing preclinical science and clinical updates on pipeline candidates, including ZN-d5, an oral BCL-2 inhibitor, and ZN-e4, an oral EGFR inhibitor. Registration is available on their website. Zentalis specializes in developing small molecule therapeutics targeting cancer-related biological pathways.
Zentalis Pharmaceuticals announces the FDA has granted Fast Track designation for its oral WEE1 inhibitor candidate, ZN-c3, aimed at treating recurrent uterine serous carcinoma (USC). This development is significant due to the aggressive nature of USC and its high recurrence rates, underscoring the urgent need for effective therapies. ZN-c3 is currently in a potential registrational Phase 2 trial, with safety updates expected in the second half of 2022. Fast Track designation allows for streamlined communication with the FDA, potentially expediting the approval process.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported financial results for Q3 2021, revealing a net loss of $10.5 million, significantly lower than the $34.7 million loss in Q3 2020. The company initiated a Phase 1/2 trial for ZN-c3 combined with gemcitabine in osteosarcoma and is progressing in a Phase 2 trial for uterine serous carcinoma. As of September 30, 2021, Zentalis holds $366.8 million in cash, expected to sustain operations through Q3 2023. Research and development expenses increased to $54 million, reflecting enhanced clinical activities.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced that CEO Anthony Sun will present at two upcoming investor conferences. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 17, 2021, at 8:40 a.m. EST, while the Jefferies London Healthcare Conference will be available on-demand starting November 18, 2021, at 8:00 a.m. GMT. Webcasts for these presentations will be accessible via the company’s website. Zentalis focuses on developing small molecule therapeutics for cancer treatment.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has initiated a Phase 1/2 trial for ZN-c3, an oral WEE1 inhibitor, in combination with gemcitabine for treating relapsed or refractory osteosarcoma. The trial aims to evaluate clinical safety and efficacy, with initial results expected in the second half of 2022. Zentalis has received orphan drug and rare pediatric disease designations from the FDA for this indication, potentially leading to a priority voucher upon approval. Osteosarcoma, primarily affecting younger patients, has a poor prognosis, highlighting the urgent need for effective therapies.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced the acceptance of six abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress, taking place virtually from September 16-21, 2021. Highlights include studies on ZN-c3, a WEE1 inhibitor, and ZN-c5, an oral selective estrogen receptor degrader, targeting advanced cancers. The posters will be accessible on the Congress platform starting September 16 at 8:30 a.m. CEST and will also appear on Zentalis' website.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced participation in two virtual investor conferences. The Morgan Stanley Global Healthcare Conference is on September 10, 2021, at 2:45 p.m. EDT, featuring a live fireside chat with CEO Anthony Sun. The H.C. Wainwright Global Life Sciences Conference follows on September 13, 2021, at 7:00 a.m. EDT, presented on demand. Webcasts will be available on the company’s website, showcasing Zentalis's focus on developing small molecule therapeutics for cancer.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the publication of its WEE1 inhibitor candidate, ZN-c3, in the Journal of Medicinal Chemistry. This selective WEE1 inhibitor aims to enhance cancer treatment efficacy by targeting the cell cycle regulator WEE1. ZN-c3 is under evaluation in multiple trials, including potential accelerated approval routes for uterine serous carcinoma. The company believes ZN-c3's profile may represent a best-in-class oncology treatment, following promising clinical results reported in June.
Zentalis Pharmaceuticals (ZNTL) reported promising new data for ZN-c3 and ZN-c5, highlighting their potential as best-in-class cancer therapies. The company successfully dosed the first patient in a Phase 2 trial for ZN-c3 targeting uterine serous carcinoma (USC). Additionally, Zentalis raised approximately $173 million in a public offering to support future milestones. The second quarter of 2021 saw a net loss of $55.1 million, driven by increased R&D expenses. As of June 30, 2021, Zentalis held $250.9 million in cash, which is expected to fund operations well into Q3 2023.